Justin Taylor, MD | Authors


Phase II Evaluates Vemurafenib/Obinutuzumab in Hairy Cell Leukemia

December 06, 2019

Justin Taylor, MD, discusses the rationale for an ongoing phase II trial that is exploring the combination of vemurafenib, a BRAF inhibitor, plus the anti-CD20 monoclonal antibody obinutuzumab in previously untreated patients with classical hairy cell leukemia.